ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Monday, November 14, 2016

9:00AM-11:00AM
Abstract Number: 1726
An Integrated Safety Data Analysis Across All Phase II and Phase III Clinical Programs for Ustekinumab in Psoriatic Arthritis, Crohn’s Disease, and Psoriasis
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1577
An Investigation of Translocator Protein As a Tissue and Peripheral Blood Biomarker of Inflammation in Rheumatoid Arthritis
Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II
9:00AM-11:00AM
Abstract Number: 1625
Analysis of a Phase 3 Study Evaluating the Efficacy of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Across Subgroups in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II
9:00AM-11:00AM
Abstract Number: 1301
Analysis of Anatomical Sites Causing Dactylitis and Their Responsiveness to Change Under TNF-Therapy in Psoriatic Arthritis By High Resolution MRI
Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI
9:00AM-11:00AM
Abstract Number: 1781
Analysis of Influences of Various Factors on the Prognosis of Acute Confusional State of Diffuse Psychiatric/Neuropsychological Syndromes in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life
9:00AM-11:00AM
Abstract Number: 1937
Analysis of Innate and Adaptive Immune Responses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)
Vasculitis - Poster II: ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1776
Analysis of Progressive Brain and Corpus Callosum Atrophy and Association with Th1 and Th2 Cytokines in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life
9:00AM-11:00AM
Abstract Number: 1919
Analysis of T Cell Repertoire Diversity of CD4+ Memory and NaïVe T Cells By Next Generation Sequencing and Its Association with Rheumatoid Arthritis Disease Parameters
T Cell Biology and Targets in Autoimmune Disease - Poster Session I
9:00AM-11:00AM
Abstract Number: 1086
Analysis of the Naive B Cell Repertoire in Belimumab Treated SLE Patients
B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's
9:00AM-11:00AM
Abstract Number: 1307
Anatomical Patterns Suggest the Involvement of Biomechanical Stress in the Pathogenesis of Erosions in Rheumatoid Arthritis
Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI
9:00AM-11:00AM
Abstract Number: 1950
ANCA-Associated Vasculitides and IgG4-Related Disease: An Overlapping Syndrome? a European Observational Study of 18 Patients
Vasculitis - Poster II: ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1116
Anti-Citrullinated Protein Antibodies Promote Synovial Fibroblasts Migration and Adhesion through a Peptidylarginine Deiminases (PAD) Dependent Pathway
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I
9:00AM-11:00AM
Abstract Number: 1499
Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease with Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications
9:00AM-11:00AM
Abstract Number: 1128
Anti-Fractalkine Monoclonal Antibody Inhibits Cartilage Destruction and Bone Erosion in Collagen-Induced Arthritis Model
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I
9:00AM-11:00AM
Abstract Number: 1383
ANTI-RO/SSA and/or ANTI-La/SSB Antibodies: Association with Mild LUPUS Manifestations in 645 Childhood-Onset Systemic LUPUS Erythematosus
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome
  • «Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 68
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology